Roundup: AITRICS' AI sepsis prediction software gets cleared in South Korea and more briefs
04 Nov 2022
Preview
Source: mobihealthnews
Credit: AITRICS
South Korea clears AITRICS' AI software for predicting patient deterioration
AI startup AITRICS has obtained clearance from South Korea's Ministry of Food and Drug Safety for its AI monitoring solution.
The South Korean startup has developed VitalCare, an AI software for predicting a patient's risk of cardiac arrest, sepsis and death within 4-6 hours in the ICU. It tracks six vital parameters, 11 haematological tests and other patient information to come up with a prediction.
AITRICS is currently working with Cleveland Clinic to validate VitalCare's performance, utilising volumes of clinical data.
Syntekabio launches cloud service platform for AI drug discovery
South Korean biotechnology company Syntekabio has unveiled its cloud service platform for AI-based drug discovery.
Developed using a proprietary supercomputing infrastructure, STB Cloud helps reduce the time and cost of drug development by simplifying, standardising, and automating the process in a single platform.
The platform works together with Syntekabio's DeepMatcher, an AI-based synthetic drug candidate discovery platform, and NGS-ARS, a next-generation sequencing platform for analysing cancer and rare genetic diseases.
Other Syntekabio AI platforms are also slated to be brought into the STB Cloud, including Neo-ARS, a new antigen prediction platform, and PGM-ARS, a multi-variant biomarker prediction and discovery platform.
The STB Cloud Global Service is set to be launched this month, starting in the United States.
LV Prasad Eye Institute leverages AI to early detect eye diseases in children
LV Prasad Eye Institute (LVPEI), an eye care network in India, has teamed up with US-based healthcare startup CognitiveCare to use AI in the early detection of eye diseases and adverse eye conditions in infants and children.
In recent years, India has seen rising cases of eye diseases like retinopathy of prematurity and myopia among children. The eye network says "active prevention and mitigation strategies are needed to control and potentially reverse both the ROP and myopia trends" in the country.
Its latest partnership will leverage CognitiveCare's AI platform that can quantify an individual or population's health risks before and after birth.
"We are also hopeful that this partnership will pave [the] way to leverage AI, deep learning, and advanced computational sciences to address several other critical eye diseases," said Dr Prashant Garg, executive chair of LVPEI.
Tags: AITRICS, South Korea, Vital Care, AI, sepsis, predictive analytics, Syntekabio, STB Cloud, AI drug discovery, cloud, LV Prasad Eye Institute, India, CognitiveCare, AI detection, eye diseases, ROP, myopia
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.